Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer
Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer
复制标题
DOI：
10.1016/j.jtho.2017.11.123
复制
发表时间：
2018-03-01
影响因子：
20.4
通讯作者：
Tomii, Keisuke
中科院分区：
文献类型：
--
作者：
Fujimoto, Daichi;Sato, Yuki;Tomii, Keisuke
Nivolumab已被证明对转移性NSCLC有效。四种程序性细胞死亡配体1 （PD-L1）免疫组织化学（IHC）检测系统可用于识别非小细胞肺癌患者中的应答者，这些检测显示出一些不同的特征。因此，在本研究中，我们评估了这些检测方法识别纳武单抗治疗应答者的能力。方法：我们回顾性分析了2016年1月至2016年9月期间接受纳武单抗治疗的晚期NSCLC患者。采用4种PD-L1免疫组化染色（28-8、22C3、SP142和SP263）。我们将患者的检测结果分为强阳性（肿瘤比例评分[TPS] >= 50%）、弱阳性（TPS 1%-49%）和阴性（TPS）
Introduction: Nivolumab has demonstrated efficacy against metastatic NSCLC. Four programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) assay systems are available for identification of responders among patients with NSCLC, and these assays show some differing characteristics. Accordingly, in this study, we evaluated the ability of these assays to identify responders to nivolumab therapy.Methods: We retrospectively analyzed patients with previously treated advanced NSCLC, who received nivolumab between January 2016 and September 2016. Specimens were stained using four PD-L1 IHC assays (28-8, 22C3, SP142, and SP263). We classified patients as having test results that were strongly positive (tumor proportion score [TPS] >= 50%), weakly positive (TPS 1%-49%), or negative (TPS